Strategic Spin-Outs: Biotechs Structure Their Progeny For Success
This article was originally published in Start Up
Executive Summary
Placing assets in new companies is a growing trend for biotech start-ups; freed to evolve differently, spin-outs are structured to increase exit options and maximize investor returns. We profile Envisia Therapeutics, F-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics.
You may also be interested in...
Spero Therapeutics LLC
Spero Therapeutics LLC was formed to develop antibiotics based on a novel mechanism, to treat infections with high unmet need. Its lead program, initiated in 2013, commercializes the research of Laurence Rahme of Mass General, who invented a method for using small molecules to inhibit MvfR, a transcription regulator utilized by gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella.
Start-Up Quarterly Statistics, Q1 2014
Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.
Biopharma Dealmaking Quarterly Statistics, Q1 2014
Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.